These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 30779375)

  • 1. Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies.
    Matsukawa Y; Takai S; Majima T; Funahashi Y; Sassa N; Kato M; Yamamoto T; Gotoh M
    Neurourol Urodyn; 2019 Mar; 38(3):941-949. PubMed ID: 30779375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study).
    Yamanishi T; Kaga K; Sakata K; Yokoyama T; Kageyama S; Fuse M; Tokunaga S
    Neurourol Urodyn; 2020 Feb; 39(2):804-812. PubMed ID: 31961963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: A randomized, prospective, comparative trial using a urodynamic study.
    Matsukawa Y; Takai S; Funahashi Y; Kato M; Yamamoto T; Gotoh M
    Neurourol Urodyn; 2017 Mar; 36(3):748-754. PubMed ID: 27060991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS).
    Kaplan SA; Herschorn S; McVary KT; Staskin D; Chapple C; Foley S; Cambronero Santos J; Kristy RM; Choudhury N; Hairston J; Schermer CR
    J Urol; 2020 Jun; 203(6):1163-1171. PubMed ID: 31895002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia: A Japanese post-marketing study.
    Takahashi S; Kato D; Tabuchi H; Uno S
    Low Urin Tract Symptoms; 2021 Jan; 13(1):79-87. PubMed ID: 32761776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic efficacy of low-dose (25 mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases.
    Chen SF; Kuo HC
    Low Urin Tract Symptoms; 2019 Apr; 11(2):O53-O58. PubMed ID: 29380517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Silodosin and Naftopidil for Efficacy in the Treatment of Benign Prostatic Enlargement Complicated by Overactive Bladder: A Randomized, Prospective Study (SNIPER Study).
    Matsukawa Y; Funahashi Y; Takai S; Majima T; Ogawa T; Narita H; Kato M; Gotoh M
    J Urol; 2017 Feb; 197(2):452-458. PubMed ID: 27615436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urodynamic Efficacy and Safety of Mirabegron Add-on Treatment with Tamsulosin for Japanese Male Patients with Overactive Bladder.
    Wada N; Iuchi H; Kita M; Hashizume K; Matsumoto S; Kakizaki H
    Low Urin Tract Symptoms; 2016 Sep; 8(3):171-6. PubMed ID: 27619782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Mirabegron in Men with Overactive Bladder Symptoms and Benign Prostatic Hyperplasia.
    Mullen GR; Kaplan SA
    Curr Urol Rep; 2021 Jan; 22(1):5. PubMed ID: 33411109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men.
    Otsuki H; Kosaka T; Nakamura K; Mishima J; Kuwahara Y; Tsukamoto T
    Int Urol Nephrol; 2013 Feb; 45(1):53-60. PubMed ID: 23212147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravesical prostatic protrusion does not compromise the therapeutic effects of Mirabegron in male patients with overactive bladder.
    Shen YC; Wang HJ; Lee WC; Chen CH; Chuang YC
    Int J Clin Pract; 2020 Sep; 74(9):e13537. PubMed ID: 32438481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus-1 associated myelopathy.
    Matsuo T; Miyata Y; Nakamura T; Satoh K; Sakai H
    Low Urin Tract Symptoms; 2019 Apr; 11(2):O65-O70. PubMed ID: 29473309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of adding mirabegron to alpha-adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms: A prospective study.
    Kwon SY; Park DJ; Seo YJ; Lee KS
    Investig Clin Urol; 2020 Jul; 61(4):419-424. PubMed ID: 32665999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urodynamic evaluation of the efficacy of mirabegron on storage and voiding functions in women with overactive bladder.
    Matsukawa Y; Takai S; Funahashi Y; Yamamoto T; Gotoh M
    Urology; 2015 Apr; 85(4):786-90. PubMed ID: 25709050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men.
    Matsuo T; Miyata Y; Kakoki K; Yuzuriha M; Asai A; Ohba K; Sakai H
    BMC Urol; 2016 Jul; 16(1):45. PubMed ID: 27473059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mirabegron as a treatment for overactive bladder symptoms in men (MIRACLE study): Efficacy and safety results from a multicenter, randomized, double-blind, placebo-controlled, parallel comparison phase IV study.
    Shin DG; Kim HW; Yoon SJ; Song SH; Kim YH; Lee YG; Joo KJ; Bae JH; Kang TW; Jeong SJ; Woo SH; Yoo ES; Son H; Koo KC; Kim SW
    Neurourol Urodyn; 2019 Jan; 38(1):295-304. PubMed ID: 30311691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Silodosin Monotherapy vs Silodosin With Tadalafil Add-on Therapy in Patients With Benign Prostatic Hyperplasia.
    Yoshida T; Kinoshita H; Shimada S; Taguchi M; Matsuda T
    Urology; 2017 Aug; 106():153-159. PubMed ID: 28431996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.